Marta Torrens
Biographic Data
| ID | 6815046 |
|---|---|
| NAME | Marta Torrens |
| GIVEN NAMES | Marta |
| FAMILY NAME | Torrens |
| SIGNATURE | TORRENS M |
| AFFILIATIONS | Universitat Autonòma de Barcelona |
| ORCID | 0000-0001-6222-4761 |
| VERIFIED | Yes |
| TOTAL WORKS | 25 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 25 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2009 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
The Optimus International Consensus Guidance for Monitoring User-Reported Outcomes of Opioid Maintenance Treatment
Opioid use disorder is a major cause of drug-related harm and mortality. These can be reduced by expanded access to evidence-based and highly effective opioid agonist maintenance treatment or therapy (OMT). There is a lack of consensus on how to assess opioid use disorder treatment outcomes, and key health outcomes are often omitted. We report the results of a Delphi study to produce service user- and public health–centred international consensus…
Sex differences in the comorbidity of patients seeking a first treatment for Alcohol Use Disorder
Background The CohRTA multicenter study aims to characterize patients undergoing a first treatment for alcohol use disorder (AUD). The objective is to analyze sex-specific differences in the comorbidity of AUD when starting the first treatment for the disorder. Methods A multicenter study was carried out between 2014 and 2021 in 6 public centers in Spain. Sociodemographic characteristics were collected, variables related to alcohol consumption, m…
Opioid Agonist Maintenance Treatment Outcomes—The Optimus International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report
Non-medical opioid use is a major public health concern causing high mortality. While opioid agonist maintenance treatment (OMT) is a key life-saving intervention, there is (a) no international consensus on opioid treatment outcomes and (b) few opioid treatment outcome studies include key (public) health outcomes, such as overdose or HIV/hepatitis C. We report the rationale and study protocol for, and preliminary results of, an ongoing internatio…
High cardiovascular risk in older patients with opioid use disorder
Synthetic cannabinoids use in a sample of opioid-use disorder patients
Cannabis is the most widely consumed illegal drug in the world and synthetic cannabinoids are increasingly gaining popularity and replacing traditional cannabis. These substances are a type of new psychoactive substance that mimics the cannabis effects but often are more severe. Since, people with opioids use disorder use widely cannabis, they are a population vulnerable to use synthetic cannabinoids. In addition, these substances are not detecte…
BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression
Results suggest a different pathogenesis for CUD-induced-MDD with higher levels of cortisol and BDNF compared with CUD-primary-MDD. Such variations should imply different approaches in treatment
A rapid assessment of take-home naloxone provision during Covid-19 in Europe
Through programme innovation supported by public guidelines, many European THN programmes managed to ensure stable or even increased THN provision during the pandemic, despite social distancing and stay-at-home orders affecting client mobility
Non-medical Use of Prescription Gabapentinoids (Gabapentin and Pregabalin) in Five European Countries
Background: Non-medical use (NMU) of prescription GABA analogs (pregabalin and gabapentin) has been reported especially in opiate dependent persons. However, by now the prevalence of NMU of gabapentinoids in the general population has not been sufficiently evaluated. The aim of this research paper is to determine the prevalence of prescription GABA analog NMU and associated demographics in five European countries with special detail of Spain. Met…
Developing an App to Screen for Dual Disorders
Background: Previous studies in Mexico undertaken at residential facilities for treating substance use disorders (SUDs) reported that the prevalence of Dual Disorders (DDs) is over 65%. DDs pose a major challenge for the Mexican health system, particularly for community-based residential care facilities for SUDs, due to the shortage of certified professionals to diagnose and treat these patients. Moreover, the lack of standardized algorithms for …
Integration of harm reduction and treatment into care centres for substance use
Responding to global stimulant use
A Multicenter Phase II Rater-Blinded Randomized Controlled Trial to Compare the Effectiveness of Eye Movement Desensitization Reprocessing Therapy vs. Treatment as Usual in Patients With Substance Use…
Background: Psychological trauma has a strong negative impact on the onset, course and prognosis of substance use disorders (SUD). Few trauma-oriented treatment approaches have been trialed, but preliminary evidence exists of the efficacy of Eye Movement Desensitization and Reprocessing (EMDR) therapy in improving clinical symptoms in SUD patients. Objective: To assess if EMDR therapy leads to: (1) reduced substance consumption; (2) an improvemen…
Perceptions and self-reported competency related to testing, management and treatment of hepatitis C virus infection among physicians prescribing opioid agonist treatment
Trends in Aids Mortality, Retention in Opioid Agonist Therapy, and HIV RNA Suppression in HIV-Infected People Who Injected Drugs from 2000 to 2015
Plasma Chemokines in Patients with Alcohol Use Disorders
Recent studies have linked changes in peripheral chemokine concentrations to the presence of both addictive behaviors and psychiatric disorders. The present study further explore this link by analyzing the potential association of psychiatry comorbidity with alterations in the concentrations of circulating plasma chemokine in patients of both sexes diagnosed with alcohol use disorders (AUD). To this end, 85 abstinent subjects with AUD from an out…
A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder
The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT 2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were ass…
The hidden web and the fentanyl problem
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs
Something New about Something Old
New psychoactive tryptamines may be a public health risk since they intend to mimic the hallucinogenic effects of regulated psychoactive drugs. Few studies describe uses and clinical effects of unregulated new psychoactive tryptamines. This study aims (1) to explore the presence of tryptamines classified as NPS among the substances delivered for analysis to a harm-reduction organization; (2) to describe the substances found in the samples after a…
Sex Differences in Psychiatric Comorbidity and Plasma Biomarkers for Cocaine Addiction in Abstinent Cocaine-Addicted Subjects in Outpatient Settings
There are sex differences in the progression of drug addiction, relapse, and response to therapies. Because biological factors participate in these differences, they should be considered when using biomarkers for addiction. In the current study, we evaluated the sex differences in psychiatric comorbidity and the concentrations of plasma mediators that have been reported to be affected by cocaine. Fifty-five abstinent cocaine-addicted subjects dia…
Low Non-structured Antiretroviral Therapy Interruptions in HIV-Infected Persons Who Inject Drugs Receiving Multidisciplinary Comprehensive HIV Care at an Outpatient Drug Abuse Treatment Center
Quality of life in a community sample of young cocaine and/or heroin users
Psychiatric, Behavioural and Social Risk Factors for HIV Infection Among Female Drug Users
Impact of Co-Occurring Psychiatric Disorders on Retention in a Methadone Maintenance Program
We assess the influence of co-occurring psychiatric disorders on retention in 189 opioid dependent patients in a methadone maintenance treatment (MMT) and determine the incidence of psychiatric co-morbidity during an 18-month follow-up period. About 68.5 % were retained in the MMT. Neither co-occurring mental disorders (chi-square = 0.303, df = 1, p = 0.622) nor methadone doses [85 (88.9) vs. 79.2 (85) mg/day, p = 0.672] were related to retention…
Psychoactive drug or mystical incense? Overview of the online available information on Spice products
The aim of the study was to foster the collection and analysis of data from web pages related to information on the consumption, manufacture and sale of Spice products, a brand name for an herbal smoking blend, sold as legal substitute for cannabis. The Google search engine was used to carry out an 8-language qualitative assessment of information available on Spice products in a sample of about 200 web sites. The level of information elicited inc…
No prominent works on this page.
Impact of Co-Occurring Psychiatric Disorders on Retention in a Methadone Maintenance Program
We assess the influence of co-occurring psychiatric disorders on retention in 189 opioid dependent patients in a methadone maintenance treatment (MMT) and determine the incidence of psychiatric co-morbidity during an 18-month follow-up period. About 68.5 % were retained in the MMT. Neither co-occurring mental disorders (chi-square = 0.303, df = 1, p = 0.622) nor methadone doses [85 (88.9) vs. 79.2 (85) mg/day, p = 0.672] were related to retention…
Psychoactive drug or mystical incense? Overview of the online available information on Spice products
The aim of the study was to foster the collection and analysis of data from web pages related to information on the consumption, manufacture and sale of Spice products, a brand name for an herbal smoking blend, sold as legal substitute for cannabis. The Google search engine was used to carry out an 8-language qualitative assessment of information available on Spice products in a sample of about 200 web sites. The level of information elicited inc…
Psychiatric, Behavioural and Social Risk Factors for HIV Infection Among Female Drug Users
Sex Differences in Psychiatric Comorbidity and Plasma Biomarkers for Cocaine Addiction in Abstinent Cocaine-Addicted Subjects in Outpatient Settings
There are sex differences in the progression of drug addiction, relapse, and response to therapies. Because biological factors participate in these differences, they should be considered when using biomarkers for addiction. In the current study, we evaluated the sex differences in psychiatric comorbidity and the concentrations of plasma mediators that have been reported to be affected by cocaine. Fifty-five abstinent cocaine-addicted subjects dia…
Low Non-structured Antiretroviral Therapy Interruptions in HIV-Infected Persons Who Inject Drugs Receiving Multidisciplinary Comprehensive HIV Care at an Outpatient Drug Abuse Treatment Center
Quality of life in a community sample of young cocaine and/or heroin users
Plasma Chemokines in Patients with Alcohol Use Disorders
Recent studies have linked changes in peripheral chemokine concentrations to the presence of both addictive behaviors and psychiatric disorders. The present study further explore this link by analyzing the potential association of psychiatry comorbidity with alterations in the concentrations of circulating plasma chemokine in patients of both sexes diagnosed with alcohol use disorders (AUD). To this end, 85 abstinent subjects with AUD from an out…
A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder
The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT 2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were ass…
The hidden web and the fentanyl problem
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs
Something New about Something Old
New psychoactive tryptamines may be a public health risk since they intend to mimic the hallucinogenic effects of regulated psychoactive drugs. Few studies describe uses and clinical effects of unregulated new psychoactive tryptamines. This study aims (1) to explore the presence of tryptamines classified as NPS among the substances delivered for analysis to a harm-reduction organization; (2) to describe the substances found in the samples after a…
Trends in Aids Mortality, Retention in Opioid Agonist Therapy, and HIV RNA Suppression in HIV-Infected People Who Injected Drugs from 2000 to 2015
Responding to global stimulant use
A Multicenter Phase II Rater-Blinded Randomized Controlled Trial to Compare the Effectiveness of Eye Movement Desensitization Reprocessing Therapy vs. Treatment as Usual in Patients With Substance Use…
Background: Psychological trauma has a strong negative impact on the onset, course and prognosis of substance use disorders (SUD). Few trauma-oriented treatment approaches have been trialed, but preliminary evidence exists of the efficacy of Eye Movement Desensitization and Reprocessing (EMDR) therapy in improving clinical symptoms in SUD patients. Objective: To assess if EMDR therapy leads to: (1) reduced substance consumption; (2) an improvemen…
Perceptions and self-reported competency related to testing, management and treatment of hepatitis C virus infection among physicians prescribing opioid agonist treatment
Integration of harm reduction and treatment into care centres for substance use
Non-medical Use of Prescription Gabapentinoids (Gabapentin and Pregabalin) in Five European Countries
Background: Non-medical use (NMU) of prescription GABA analogs (pregabalin and gabapentin) has been reported especially in opiate dependent persons. However, by now the prevalence of NMU of gabapentinoids in the general population has not been sufficiently evaluated. The aim of this research paper is to determine the prevalence of prescription GABA analog NMU and associated demographics in five European countries with special detail of Spain. Met…
Developing an App to Screen for Dual Disorders
Background: Previous studies in Mexico undertaken at residential facilities for treating substance use disorders (SUDs) reported that the prevalence of Dual Disorders (DDs) is over 65%. DDs pose a major challenge for the Mexican health system, particularly for community-based residential care facilities for SUDs, due to the shortage of certified professionals to diagnose and treat these patients. Moreover, the lack of standardized algorithms for …
High cardiovascular risk in older patients with opioid use disorder
Synthetic cannabinoids use in a sample of opioid-use disorder patients
Cannabis is the most widely consumed illegal drug in the world and synthetic cannabinoids are increasingly gaining popularity and replacing traditional cannabis. These substances are a type of new psychoactive substance that mimics the cannabis effects but often are more severe. Since, people with opioids use disorder use widely cannabis, they are a population vulnerable to use synthetic cannabinoids. In addition, these substances are not detecte…
BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression
Results suggest a different pathogenesis for CUD-induced-MDD with higher levels of cortisol and BDNF compared with CUD-primary-MDD. Such variations should imply different approaches in treatment
A rapid assessment of take-home naloxone provision during Covid-19 in Europe
Through programme innovation supported by public guidelines, many European THN programmes managed to ensure stable or even increased THN provision during the pandemic, despite social distancing and stay-at-home orders affecting client mobility
Sex differences in the comorbidity of patients seeking a first treatment for Alcohol Use Disorder
Background The CohRTA multicenter study aims to characterize patients undergoing a first treatment for alcohol use disorder (AUD). The objective is to analyze sex-specific differences in the comorbidity of AUD when starting the first treatment for the disorder. Methods A multicenter study was carried out between 2014 and 2021 in 6 public centers in Spain. Sociodemographic characteristics were collected, variables related to alcohol consumption, m…
Opioid Agonist Maintenance Treatment Outcomes—The Optimus International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report
Non-medical opioid use is a major public health concern causing high mortality. While opioid agonist maintenance treatment (OMT) is a key life-saving intervention, there is (a) no international consensus on opioid treatment outcomes and (b) few opioid treatment outcome studies include key (public) health outcomes, such as overdose or HIV/hepatitis C. We report the rationale and study protocol for, and preliminary results of, an ongoing internatio…
The Optimus International Consensus Guidance for Monitoring User-Reported Outcomes of Opioid Maintenance Treatment
Opioid use disorder is a major cause of drug-related harm and mortality. These can be reduced by expanded access to evidence-based and highly effective opioid agonist maintenance treatment or therapy (OMT). There is a lack of consensus on how to assess opioid use disorder treatment outcomes, and key health outcomes are often omitted. We report the results of a Delphi study to produce service user- and public health–centred international consensus…
Medicine (25 works) · Psychiatry (15 works) · Internal Medicine (12 works) · Opioid Use Disorder Treatment (11 works) · Psychology (11 works) · HIV, Drug Use, Sexual Risk (8 works) · Substance Abuse Treatment and Outcomes (8 works) · Public health (7 works) · Forensic Toxicology and Drug Analysis (6 works) · Clinical Psychology (5 works)